

2019 Clinical Outcomes Formulary

List of Removals and Updates



Effective January 1, 2019, the formulary status of the following medications will change. The tables below summarize the modifications to the WellDyneRx Clinical Outcomes Formulary.

Excluded to Preferred 2019:

Therapeutic Category	Drug(s)
Antidiabetic Therapy - Injectables	BASAGLAR
	OZEMPIC
	VICTOZA
Anti-Inflammatory Agents	RENFLEXIS
Hemanitics and Blood Cell Stimulators	ZARXIO

Non-Preferred to Preferred 2019:

Therapeutic Category	Drug(s)
Hemanitics and Blood Cell Stimulators	NIVESTYM

Preferred to Non-Preferred 2019:

Therapeutic Category	Drug(s)	Alternative(s)
Antidiabetic Therapy - Injectables	TOUJEO	BASAGLAR, LEVEMIR, TRESIBA
Antidiabetic Therapy - Oral	FARXIGA	STEGLATRO
	JARDIANCE	STEGLATRO
Antihypertensive - Renin Inhibitors	TEKTURNA, TEKTURNA-HCTZ	irbesartan, losartan or valsartan plus hydrochlorothiazide
Anti-Inflammatory Agents	REMICADE	RENFLEXIS, INFLECTRA
Hemanitics and Blood Cell Stimulators	NEUPOGEN	GRANIX, NIVESTYM, ZARXIO
	NEULASTA	FULPHILA
Hormone Replacement Therapy	ANDROGEL	testosterone cypionate, testosterone enanthate, testosterone solution

Preferred to Drug Exclusion 2019:

Therapeutic Category	Drug(s)	Alternative(s)
Antidiabetic Therapy - Injectables	BYETTA, BYDUREON	OZEMPIC, TRULICITY, VICTOZA
	LANTUS	BASAGLAR, LEVEMIR, TRESIBA

This list is not comprehensive and does not contain every possible formulary alternative. Formulary items are subject to change.